Neurogene Inc NGNE.OQ NGNE.O is expected to show no change in quarterly revenue when it reports results on May 8 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Neurogene Inc is for a loss of $1.06 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neurogene Inc is $46.00, above its last closing price of $15.11.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -1.13 | -0.99 | Beat | 12.4 | |
Sep. 30 2024 | -1.22 | -1.22 | -1.19 | Beat | 2.6 |
Jun. 30 2024 | -1.04 | -1.05 | -1.09 | Missed | -3.8 |
Mar. 31 2024 | -1.12 | -1.13 | -1.00 | Beat | 11.9 |
Dec. 31 2023 | -1.17 | -1.17 | -1.51 | Missed | -28.7 |
-1.64 | | ||||
-0.80 | |||||
Mar. 31 2023 | -2.51 | -2.50 | -5.12 | Missed | -104.8 |
This summary was machine generated May 6 at 13:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。